Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.
Investor's Business Daily on MSN
Why Pharming, a top 3% biotech stock, just took a double-digit beating
Biotech stock Pharming was pummeled Monday after the FDA rejected the company's request to expand the patient pool for Joenja ...
Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results